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INTRODUCTION
Corticotropin releasing factor (CRF) is a 41 amino acid
peptide that is highly expressed throughout areas of the cen-
tral nervous system (CNS). In the adult, CRF has been shown
to be involved in the stress response mediated by the hypotha-
lamo-pituitary-adrenal (HPA) axis, as well as being involved
in some degenerative brain disorders (1-3). In adult mouse
cerebellum, CRF has been localized to two major afferent
systems, climbing fibers and mossy fibers, and it has been
shown to function as a neuromodulator in adult cerebellar
circuits (4-6).
Several observations suggest that CRF may have a trophic
function in the developing cerebellum, as compared to its
neuromodulatory role in the adult cerebellum. In the devel-
oping mouse cerebellum, CRF is initially detected at embry-
onic day 10 (E10) in widely dispersed profile, and is present
throughout all pre- and postnatal stages of cerebellar devel-
opment; however, its localization in phenotypic axon termi-
nals (climbing and mossy fibers) begins to emerge at post-
natal day 10 (P10) (7, 8). Although CRF receptors (CRF-Rs)
also are present on populations of neurons and glia at birth,
a physiological effect of CRF on Purkinje cell firing rate is
recorded at P12-P16 (8-10). Of particular note is a widespread
distribution of CRF throughout cerebellum during embry-
onic and early postnatal development (8). The period between
the initial appearance of CRF in cerebellum and its localiza-
tion in cerebellar afferent fibers is critical in cerebellar devel-
opment (7). In addition, proliferation or apoptosis of imma-
ture cerebellar neurons is found during this period.
CRF exerts its effects by binding to either the type 1 (CRF-
R1) or the type 2 CRF receptor (CRF-R2). The high affinity
receptor, CRF-R1, has one functional and several non-func-
tional splice variants (11). Although CRF-R2 has three func-
tional splice variants that are referred to as CRF-R2 , CRF-
R2 , and CRF-R2 , only CRF-R2 has a major distribu-
tion in the central nervous system (12). We will designate
the functional splice variant of CRF-R1 and CRF-R2 as
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Corticotropin-releasing Factor (CRF) and Urocortin Promote the 
Survival of Cultured Cerebellar GABAergic Neurons Through the 
Type 1 CRF Receptor
Corticotropin releasing factor (CRF) is known to be involved in the stress response
and in some degenerative brain disorders. In addition, CRF has a role as a neuro-
modulator in adult cerebellar circuits. Data from developmental studies suggest a
putative role for CRF as a trophic factor during cerebellar development. In this study,
we investigated the trophic role for CRF family of peptides by culturing cerebellar
neurons in the presence of CRF, urocortin or urocortin II. Primary cell cultures of
cerebella from embryonic day 18 mice were established, and cells were treated for
either 1, 5 or 9 days with Basal Medium Eagles complete medium alone or com-
plete medium with 1  M CRF, urocortin, or urocortin II. The number of GABA-pos-
itive neurons in each treatment condition was counted at each culture age for moni-
toring the changes in neuronal survival. Treatment with 1  M CRF or 1  M urocortin
increased the survival of GABAergic neurons at 6 days in vitro and 10 days in vitro,
and this survival promoting effect was abolished by treatment with astressin in the
presence of those peptides. Based on these data, we suggest that CRF or urocortin
has a trophic role promoting the survival of cerebellar GABAergic neurons in cul-
tures.
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CRF-R1 and CRF-R2, respectively, in this paper. Each
receptor subtype has unique binding characteristics (13), and
both CRF-R1and CRF-R2are differentially localized in mouse
cerebellum during development (14-16). These results sup-
port that cerebellar neurons or astrocytes can be affected by
ligands for CRF receptors during development. Our working
hypothesis is that CRF or its family of peptides has a role
during development that is distinct from that in mature
brain, possibly acting as a trophic factor that influences neu-
ronal survival and/or differentiation during cerebellar devel-
opment. Previous reports have shown that CRF has a neuro-
protective effect when neurons are exposed to a hypoxic or
neurotoxic environment (17, 18), while it has a mitogenic
effect on immature astrocytes (19).
Recently, several members of CRF family of peptides,
including urocortin (urocortin I), urocortin II and urocortin
III, were identified (20-22). Urocortin II and III are selective
ligands for CRF-R2 (20, 22), whereas urocortin may bind to
either CRF-R1 or CRF-R2, but with a higher affinity for CRF-
R2. The detailed cellular localization of urocortin and uro-
cortin II in the developing and adult cerebella are yet to be
determined; however, based on studies on the distribution of
urocortin positive neurons (23), there are several nuclei that
could be extrinsic sources of urocortin to the cerebellum. One
possible influence that CRF family of peptides might have
on developing neurons is to increase survival. We tested this
possibility by culturing cerebellar neurons from E18 mice in
the absence and in the presence of CRF, urocortin or urocortin
II. The findings presented here suggest that CRF or urocortin
might have a role in promoting the survival of GABAergic
interneurons during early cerebellar development.
MATERIALS AND METHODS
Primary cerebellar neuron culture
Primary cell cultures of cerebella from E18 mice were estab-
lished following the methods of Fischer (24) and Schilling
et al. (25). Briefly, eighteen days after mating, pregnant
C57BL/6 mice were anesthetized using an intraperitoneal
injection of 2.5% Avertin (0.2 mL/10 g). The fetuses were
removed, decapitated, and placed in phosphate-buffered saline
(PBS). The cerebella were dissected from the brainstem and
the meninges were removed. The PBS then was replaced
with Basal Medium Eagles solution (BME Complete Medi-
um) with transferrin (100  g/mL), aprotinin (1  g/mL), selen-
ite (30 nM), triiodothyronine (0.2 ng/mL), insulin (10  g/
mL), NaHCO3 (26.18 mM), glucose (0.25%), pyruvate (1
mM), glutamate (2 mM), and bovine serum albumin (BSA)
(1.010 mg/mL) plus 5% heat-inactivated fetal bovine serum.
The cerebella then were triturated 15 times before the cells
were passed through a 40  m cell strainer (BD Biosciences,
Bedford, MA, U.S.A.). After centrifugation at 150×g for 5
min, the pellet was resuspended in BME Complete Medium
with 5% heat-inactivated fetal bovine serum. Cells then were
counted using a hemocytometer (Bright-line; Hausser Sci-
entific, Horsham, PA, U.S.A.) and plated at a density of 100
×103 cells/cm2 into a four-chamber (1.8 cm2) culture slide
(Lab-Tek; Nalge Nunc International, Rochester, NY, U.S.A.)
that was pre-treated with poly-D-lysine (10 mg/100 mL).
The cultures were incubated in 10% CO2 at 37℃. One day
after plating (at 1 day in vitro; 1 DIV), the cells were fed with
serum-free BME Complete Medium containing the various
agents as delineated below. Every 3 days, half the volume of
medium was removed and replaced with fresh complete medi-
um containing the same appropriate agents. All procedures
involving animals have been approved by Sungkyunkwan
University School of Medicine Institutional Animal Care and
Use Committee and conform to NIH guidelines.
Each culture was treated for either 1 day, 5 days or 9 days
with one of the following conditions: a) BME complete medi-
um only (control), b) BME complete medium with 1  M
CRF, c) BME complete medium with 1  M urocortin, d)
BME complete medium with 1  M urocortin II, e) BME
complete medium with 1  M astressin or f) BME complete
medium with 1  M astressin in the presence of either 1  M
CRF, 1  M urocortin or 1  M urocortin II. At 1, 5 or 9 days
of treatment (DT), cultures were fixed with 4% paraformalde-
hyde solution for immunocytochemistry. A minimum of
three independent experiments per each condition were per-
formed. We have tried several cell plating densities for cul-
tures and found that 100×103 cells/cm2 cell plating density
is suitable for demonstrating the effect of CRF and its fami-
ly of peptides. The serum-free culture medium (BME com-
plete) used in the study has been shown previously to sup-
press cell proliferation, to support the survival of neuronal
cells, to have less than 5% of astrocytes in relation to total
number of cells, and to eliminate epithelioid cells such as
fibroblasts (24).
Immunocytochemistry
Cells in culture were identified using double-label immu-
nofluorescence technique. Briefly, cultures were fixed with
4% paraformaldehyde, 0.1 M phosphate buffer (pH 7.1),
50 mM sucrose, and 0.4 mM CaCl2 for 30 min, and then
rinsed with PBS
+ (PBS containing 0.1% saponin, 0.02%
sodium azide, and 1 mg/mL BSA). Cells were incubated in
primary antibodies at 4℃ overnight, rinsed with PBS
+, and
incubated in species-specific secondary antibodies for 2 hrs
at room temperature. After rinsing with PBS
+, slides were
coverslipped with Immu-Mount and sealed with clear fin-
gernail polish to avoid dehydration.
Image acquisition and analysis
Using a Zeiss Axiophot 2 fluorescence microscope (Zeiss,520 J.-S. Choi, T.T.H. Pham, Y.-J. Jang, et al.
Germany) and Axiovision 3.0 Image Acquisition System
(Zeiss, Germany), the acquisition time and gain were stan-
dardized to obtain the optimal images. For each slide, a series
of consecutive digital images following a horizontal line (180
m2/sample, spanning the width of each chamber) were
acquired to ensure that a uniform area was analyzed and an
adequate sample size for quantification was obtained. The
number of GABA-positive neurons was counted for moni-
toring the changes in neuronal survival and the cell counts
were expressed as means±standard deviations (a minimum
of 400 cells per condition). Significance was determined using
Student’s t-test, two-tailed.
Chemicals and antibodies
The following chemicals were obtained from Sigma: apro-
tinin, BSA, glucose, glutamate, insulin, lysine, pyruvate,
saponin, selenite, sodium bicarbonate, sodium chloride, sodi-
um phosphate, sucrose, triiodothyronine, and transferrin.
The following chemicals were obtained from various sources
as indicated: Basal Medium Eagles (BME) (Invitrogen-Gibco,
Carlsbad, CA), human/rat CRF (Bachem, San Carlos, CA),
urocortin (Bachem, San Carlos, CA), urocortin II (Bachem,
San Carlos, CA), astressin (Bachem, San Carlos, CA), fetal
bovine serum (Hyclone, Logan, UT), Immu-Mount (Thermo
Shandon, San Jose, CA), sodium azide (EM Sciences, Hatfield,
PA), and paraformaldehyde (EM sciences, Hatfield, PA).
Primary antibodies were used as follows: rabbit anti-GABA
IgG (1:1,000) (Sigma), goat anti-CRF-R1 (1:500) (Santa
Cruz Biotechnology, Santa Cruz, CA) and goat anti-CRF-R2
(1:500) (Santa Cruz Biotechnology, Santa Cruz, CA). Fluo-
rescent secondary antibodies were used as follows: Alexa 488-
labeled donkey anti-rabbit IgG (Molecular Probes, Eugene,
OR) or Alexa 546-labeled donkey anti-goat IgG (Molecular
Probes, Eugene, OR) was used in combination with anti-
GABA or anti-CRF receptor antibodies, respectively. All
secondary antibodies were used at 1:1,000 dilutions.
RESULTS
General appearance of cultures
To determine if CRF or its family of peptides enhances
the survival of GABAergic neurons in growth-promoting
culture medium, we used primary cell cultures using cere-
bellar cells from E18 mice because neurons that are known
to be GABAergic have been born by this age and these cul-
tures have been reported to contain a variety of cerebellar
GABAergic interneurons including basket cells, stellate cells,
and/or Golgi cells, which are labeled with anti-GABA anti-
body. Immunocytochemistry indicated that our cultures con-
tained numerous GABAergic interneurons and only a few
scattered Purkinje neurons, identified by calbindin immuno-
cytochemistry (data not shown). To determine if the control
culture condition (BME complete) affects the survival of
GABAergic interneurons even without treatment with CRF
family of peptides, cell counts were made for GABAergic
interneurons at each culture age. As for plating density of
cells in culture, our preliminary studies indicated that higher
plating densities than 100×103 cells/cm2 masked the effect
of CRF, possibly due to endogenous factors that promote cell
survival; increasing the plating density to 150×103 cells/cm2
partially reduced the observed effects, while little effect was
observed when the plating density was 200×103 cells/cm2
or higher. Based on the previous data, this study was conduct-
ed using a plating density of 100×103 cells/cm2.
The survival and maturation of GABAergic interneurons
in control cultures
Images of the control cultures at each culture age are shown
in Fig. 1. The immunocytochemical labeling for GABA
shows that our cultures have a significant number of GABAer-
gic interneurons at each culture age, thus, these cultures can
serve as a good model for studying the influence of possible
trophic factors on cerebellar GABAergic interneurons. At 1
DIV (Fig. 1A), most GABAergic neurons in culture are pre-
sent isolated from each other and show immature morphol-
ogy. Most GABAergic neurons do not yet show any promi-
nent neurite growth at this culture age, and only a few neu-
rons have short neurites growing from their somata, which
appear as filopodia or lamellopodia. At 2 DIV, the number
of GABA-immunopositive neurons in control cultures dec-
reases to 60% of that at 1 DIV (Fig. 2). Some GABAergic
neurons show more differentiated morphology with one or
two neurites around their somata, and neuronal cell bodies
are present adjacent to each other (Fig. 1D, 3A). At 6 DIV,
the number of surviving GABAergic interneurons further
decreases compared to 2 DIV (Fig. 2), but most neurons show
more mature morphology with multiple long neurites around
their somata (Fig. 1G). In addition, there is extensive growth
of neurites on the substrate between neurons at 6 DIV; the
neurites come in very close proximity to, or make contact
with, each other at 6 DIV. At 10 DIV, the number of GABA-
immunopositive neurons does not further decrease compared
to 6 DIV (Fig. 2). The GABAergic interneurons in cultures
show fully mature morphology with highly branched long
neurites, which form an extensive network between multi-
ple neurons (Fig. 1J, 3D). Based on these observations, it is
evident that these culturing conditions will permit growth
of healthy cerebellar GABAergic interneurons.
CRF receptor expression in cultured cerebellar GABAergic
interneurons
For a neuron to be responsive to some kind of ligands, it
should have specific receptors on their surface. To verify theCRF-induced Neuronal Survival in Culture 521
presence of CRF receptors on neurons under these culturing
conditions, cerebellar cultures were fixed at 1, 2, 6, and 10
DIV and labeled with antibodies to CRF-R1 or CRF-R2. The
representative images, from the same fields as shown in Fig.
1A, 1D, 1G, 1J, 3A and 3D are presented in Fig. 1B and
1C, 1E and 1F, 1H and 1I, 1K and 1L, 3B and 3C, and 3E
and 3F, respectively. At 1 or 2 DIV in control culture, the
majority of GABA-immunopositive neurons are also positive
for CRF-R1 (Fig. 1B; 1 DIV, Fig. 1E; 2 DIV) or CRF-R2 (Fig.
3B; 2 DIV), indicating that they have the ability to respond
to CRF or its family of peptides. There exist some CRF-R1
or CRF-R2 immunopositive cells that do not show labeling
for GABA (Fig. 1B, 1E, 1H, 1K, 3B and 3E, white arrows;
Fig. 1C, 1F, 1I, 1L, 3C and 3F, black arrows); these CRF-R1
or CRF-R2 positive, but not GABA immunopositive cells
are supposed to be another kind of cerebellar neurons, the
granule cells, because those cells are not labeled for calbindin,
a marker for Purkinje cells, nor are they labeled for glial fib-
rillary acid protein (GFAP), a marker for astrocytes (data not
shown). Further study is yet needed to identify these cells
that are not labeled for GABA, calbindin or GFAP. Most
GABAergic neurons appear to be also positive for CRF-R1
A B C
D E F
G H I
J K L
Fig. 1. Images of representative cells cultured in BME complete (control) media. The same field is shown as GABA-labeled fluorescent
image (left column), CRF-R1-labeled fluorescent image (middle column), and DIC image (right column). Cells are cultured in BME com-
plete (control) media for 10 days, and fixed at 1, 2, 6 or 10 DIV, followed by double-immunolabeling for GABA and CRF-R1. Not all CRF-
R1-positive cells are immunopositive for GABA (B, E, H, K, white arrows; C, F, I, L, black arrows). (A-C) 1 DIV, (D-F) 2 DIV, (G-I) 6 DIV, (J-
L) 10 DIV. Cell plating density=100×10
3 cells/cm
2. 
DIV, days in culture. Magnification; ×200.522 J.-S. Choi, T.T.H. Pham, Y.-J. Jang, et al.
and CRF-R2 under all experimental conditions from 1 DIV
to 10 DIV, indicating that the treatments with CRF family
of peptides do not alter the expression of CRF receptors in
these cultures.
Survival of GABAergic interneurons in treatment with CRF
family of peptides
Based on our hypothesis, one putative role for CRF and
its family of peptides is that they act to influence cell sur-
vival during cerebellar development. Therefore, cultures were
treated for one, five or nine days with 1  M CRF (Fig. 4), 1
M astressin (Fig. 2), 1  M urocortin (Fig. 5) or 1  M uro-
cortin II (Fig. 5). While the overall health of the cultures in
each experimental condition appears to be fine, the number
of surviving GABAergic neurons is altered in specific treat-
ment conditions as the duration of treatment increases (at 5
DT and 9 DT). 
Treatment with 1  M CRF for 1 day (1 DT, at 2 DIV) does
not show any change in the survival of GABAergic neurons
in culture compared to control culture (BME complete) (Fig.
4). However, treatment with CRF begins to show a signifi-
cant increase in the survival of GABAergic neurons at 5 DT
(6 DIV) when compared to the control culture (BME com-
plete), and the increased survival of GABAergic neurons is
maintained through 9 DT (10 DIV). At 5 DT with 1  M
CRF, the number of GABAergic interneurons is 66% higher
than control level, and this value appears to be statistically
significantly higher, suggesting a role for CRF that might
promote the survival of cerebellar GABAergic neurons in
cultures. At 9 DT with 1  M CRF, the average number of
surviving GABAergic neurons is 63% higher than control
level, and this value also appears to be significantly higher
in statistics, suggesting that the survival promoting effect
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Fig. 2. The number of GABA immunopositive neurons in cultures.
Primary cerebellar GABAergic neurons were cultured in control
(BME complete) media (bright left column) or in the presence of
1  M astressin (dark right column). The number of GABA-positive
neurons per image (180  m
2/sample) was counted, and expressed
as mean value±standard deviation of the mean (a minimum of
400 cells per culture age was counted). At 2 DIV in control culture,
the number of GABA-immunopositive neurons decreases to 60%
of that in 1 DIV (no treatment). At 6 DIV in control culture, the num-
ber of surviving GABAergic interneurons further decreses to 45%
of that in 2 DIV, or 27% of that in I DIV. At 10 DIV in control culture,
the number of GABAergic neurons does not further decrease
compared to 6 DIV, and maintains almost the same level as 6
DIV. Treatment with 1  M astressin alone does not result in any
change in the survival of GABAergic neurons, when compared
to control at each culture age. Significance was determined using
Student’s t-test, two-tailed. Cell plating density=100×10
3 cells/cm
2.
DIV; days in culture, DT; Days in treatment.
A B C
D E F
Fig. 3. Images of representative cells cultured in BME complete (control) media. The same field is shown as GABA-labeled fluorescent
image (left column), CRF-R2-labeled fluorescent image (middle column), and DAPI-labeled fluorescent image (right column). Not all CRF-
R2-positive cells are immunopositive for GABA (B,C,Eand F, white arrows) (A-C) 2 DIV, (D-F) 10 DIV. Cell plating density=100×10
3 cells/cm
2. 
DIV, days in culture. Magnification; ×200.
Control (BME complete)
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of CRF in our cultures is maintained through this culture
age. To confirm that the survival promoting effect at 5 DT
and 9 DT is actually mediated by 1  M CRF treatment, we
treated the cultures with 1  M astressin, the specific antag-
onist to both subtypes of CRF receptor, in the presence of 1
M CRF. As a result, 1  M astressin treatment abolished the
survival promoting effect of CRF at both 5 DT and 9 DT
(Fig. 4); statistical analysis for the effect of 1  M astressin
treatment in the presence of 1  M CRF showed that there
was no statistically significant difference in GABAergic cell
numbers between treated culture and control culture at both
5 DT and 9 DT. Higher concentration of antagonist, 10  M
astressin, also has been employed to compare the antagonis-
tic effect between various concentrations of astressin in the
presence of 1  M CRF, and as a result, 10  M astressin also
appeared to be effective to abolish the survival promoting
effect of CRF (data not shown). It is possible that astressin
also can affect the survival of cerebellar GABAergic interneu-
rons in cultures, although it is not a physiological agent that
is naturally present in vivo. Thus, to determine any possible
effect of astressin on the survival of GABAergic neurons in
vitro, we treated cultures with 1  M astressin alone in BME
complete media. The presence of astressin at 1  M in cultures
did not show any significant change on the survival of GABA-
ergic neurons, compared to control (Fig. 2); therefore, we can
suggest that in our cultures, astressin abolished the survival
promoting effect of CRF by antagonizing CRF receptors. 
In addition to CRF, we also treated cultures with other
members of CRF family of peptides, urocortin and urocortin
II. Cultures treated with 1  M urocortin resulted in a signifi-
cant increase in the survival of GABAergic interneurons at
5 DT and 9 DT compared to control (Fig. 5), whereas treat-
ment with 1  M urocortin II did not result in any significant
change in cell survival at all culture ages (Fig. 5). To confirm
that the survival promoting effect of urocortin was mediated
through CRF receptors, we treated cultures with 1  M ast-
ressin in the presence of urocortin. As a result, 1  M astressin
treatment abolished the survival promoting effect of 1  M
urocortin at both 5 DT and 9 DT (Fig. 5); statistical analy-
sis of the effect of 1  M astressin treatment in the presence
of 1  M urocortin showed that there was no statistically
significant difference between treated culture and control
culture, which suggests that the survival promoting effect
was made by treatment with 1  M urocortin through CRF
receptors. 
DISCUSSION
E18 mice cerebella, which are used in this study for cul-
turing neurons, contain populations of cerebellar neurons
including post-mitotic Purkinje cells; GABAergic interneu-
rons including basket, stellate, and Golgi cells; nuclear neu-
rons; and immature granule cells; as well as populations of
primitive astrocytes and Bergmann glia (26). Because neu-
ronal survival following the dissociation procedure is the
greatest for cell populations that have not yet developed exten-
sive neurites and are still undergoing mitosis and/or migra-
tion, the neurons that are most likely to survive in our cul-
tures include the GABAergic interneurons, i.e., basket cells,
stellate cells, and Golgi cells. While most of these GABAer-
gic interneurons are born between E12 and E15 in the ven-
tricular zone, data show that these neurons continue to divide
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Fig. 4. Effect of CRF on GABAergic neurons in culture. Primary
cerebellar cultures were treated with 1  M CRF alone (middle
column), or 1  M astressin in the presence of 1  M CRF (right
column), for 1, 5, or 9 days (DT). The number of GABA-positive
neurons per image (180  m
2/sample) was counted, and present-
ed as mean value±standard deviation of the mean (a minimum
of 400 cells per culture age was counted). Significance was deter-
mined using Student’s t-test, two-tailed. *represents p<0.05, with
respect to control at the corresponding age. Cell plating density=
100×10
3 cells/cm
2. DIV, days in culture; DT, days in treatment.
* * * *
Control (BME complete)
1 M  CRF
1 M  CRF+1 M  astressin
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Fig. 5. Effect of urocortin and urocortin II on GABAergic neurons
in culture. Primary cerebellar cultures were treated with 1  M uro-
cortin alone (2nd column), 1  M astressin in the presence of 1  M
urocortin (3rd column), or 1  M urocortin II alone (4th column) for
1, 5, or 9 days (DT). The number of GABA-positive neurons per
image (180  m
2/sample) was counted, and presented as mean
value±standard deviation of the mean (a minimum of 400 cells
in each culture condition was counted). Significance was deter-
mined using Student’s t-test, two-tailed. *represents p<0.05, with
respect to control at the corresponding age. Cell plating density=
100×10
3 cells/cm
2. DIV, days in culture; DT, days in treatment.
Control (BME complete)
1 M  urocortin
1  M urocortin+1  M astressin
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as they migrate through cerebellar white matter and cortex
(27); therefore, these neurons still remain in an immature
state at E18 when they are used for culture, and as a result,
many cells survive in culture. We confirmed that most neu-
rons that survived in our culture system following dissocia-
tion procedure were GABAergic interneurons by doing im-
munocytochemistry for GABA.
In a previous study in which cerebellar cells were plated
at a high density and grown in media containing serum,
astrocytes without neurons were present in culture, and CRF
treatment showed an increased number of astrocytes com-
pared to cultures grown without CRF (19). In our cultures,
we eliminated glial cells by plating cells at a low density, as
well as using culture media that contained no serum, but
contained a supplement that allowed neuronal survival. In
addition, the low plating density used in our cultures has an
advantage in minimizing the influence of endogenous fac-
tors produced by other cells in culture, while it still allows
GABAergic interneurons to survive.
The decrease of GABAergic interneurons in control cultures
is the greatest during the first day following removal of serum
from the culture media. There should be many cells that
were damaged during dissociation procedure, and as a result,
those cells would die rapidly within a few days following cell
plating. At 6 DIV, the number of GABAergic interneurons
further decreases in control culture. The decrease of GABAer-
gic neurons during this period may still represent death of
cells that were damaged during dissociation procedure, or
partially represent death of cells that can not obtain enough
endogenous factors released from other cells, including glia,
due to the low plating density used in our culture. However,
the number of GABAergic neurons does not further decrease
after 6 DIV, and almost the same number of GABAergic
neurons survive at 10 DIV. This finding may represent that
cells that were damaged during dissociation procedure or
poorly supplied with endogenous factors have been eliminat-
ed from culture by 6 DIV. Although only 25% of GABAer-
gic neurons that were originally plated on the substrate sur-
vive at and after 6 DIV, our data show that enough number
of GABAergic neurons needed for experiment finally survive
in culture, so that this culture system is a good in vitro model
for studying the trophic effect of CRF family of peptides on
the survival of cerebellar GABAergic neurons.
Both subtypes of CRF receptors are expressed in the majori-
ty of GABAergic neurons in control cultures from 1 DIV
through 10 DIV, and no obvious change is found in the
intensity of immunolabeling between culture ages. Previous
reports showed that the expression of CRF receptor was reg-
ulated reciprocally depending on the level of CRF that were
present in local areas of brain (28). However, in our cultures,
treatment with CRF family of peptides at 1  M concentra-
tion does not induce any remarkable change in the expres-
sion level of CRF receptors on GABAergic neurons. Although
the mechanism regulating the expression of CRF receptor
in cultured neurons as well as in cerebellum during early
period of development is not yet clear, the known mechanism
by which CRF regulates the expression of CRF receptors in
a reciprocal manner may not work in culture system.
Based on our data, 55% of GABAergic neurons have died
in control culture during 4 days from 2 DIV to 6 DIV, but
in the presence of 1  M CRF, only 26% of neurons have died
during the same period, which represents that 1  M CRF
treatment reduces neuronal death in culture. Considering
this finding together with the possible causes for neuronal
death during the first several days in culture, we can suggest
that CRF may be effective to promote the survival of neurons
that were not severely damaged or poorly supplied with endo-
genous factors. At 10 DIV, treatment with 1  M CRF incre-
ases the neuronal survival by 63% when compared to control.
Based on our data, the survival promoting effect induced by
1  M CRF appears to be almost the same at both 6 DIV and
10 DIV. Considering that the average numbers of surviving
GABAergic neurons are almost the same at both culture ages
in control cultures, we can conclude that 1  M CRF treat-
ment does not induce proliferation of immature GABAergic
neurons in cultures, but it shows a protective effect reduc-
ing cell loss that occurs following dissociation procedure or
in a poor nutritional condition.
We treated cultures with other members of CRF family
of peptides, urocortin and urocortin II, to investigate which
subtype of CRF receptor is involved in the possible protec-
tive mechanism induced by CRF family of peptides, as well
as to determine the effect of each peptide on cultured GABA-
ergic neurons. Based on the ligand specificities for CRF-R1
and CRF-R2, we can compare the role for each subtype of
CRF receptor in mediating the effect of CRF family of pep-
tides on cultured neurons. Based on our data, CRF-R1 may
have a role in the mechanism that regulates the survival of
cultured GABAergic neurons in the presence of CRF or uro-
cortin, while CRF-R2 may not have a role in the mechanism.
Although our data show that urocortin is effective in pro-
moting the neuronal survival in cultures, the detailed infor-
mation about the spatial and temporal expression of urocortin
and urocortin II during cerebellar development, as well as
in adult cerebellum, is not yet clear; therefore, further study
is needed to clarify the role for urocortins in cerebellum dur-
ing development and in adult.
Our data indicate that treatment with 1  M astressin abol-
ishes the survival promoting effect of CRF or urocortin at
both 6 DIV and 10 DIV. In addition, astressin does not have
any trophic effect, nor does it have toxic effect on cultured
GABAergic neurons. Considering the receptor specificities
for CRF family of peptides as well as the role for astressin,
we can suggest that the survival promoting effect of CRF
and urocortin on cultured GABAergic neurons may be medi-
ated by the type 1 CRF receptor. 
Although the mechanism by which CRF or urocortin in-
creases the survival of cultured GABAergic neurons is not yetCRF-induced Neuronal Survival in Culture 525
known, one possible mechanism has been suggested recently
by Radulovic et al. (29). They found that a cytoprotective
effect of CRF in Y79 human retinoblastoma cells is exerted
by suppressing pro-apoptotic pathways, probably at a site
upstream from procaspase-3. Since GABAergic neurons in
our cultures have been shown to express CRF-R1 extensively,
it is not inconceivable that the survival promoting effect of
CRF or urocortin reported in this study might employ a sim-
ilar mechanism. Additional study is needed to confirm such
a hypothesis. The findings presented in this study suggest a
possibility that CRF or urocortin is capable of influencing
cerebellar development by increasing neuronal survival in
GABAergic neurons when cells are apoptotic or poorly sup-
plied with endogenous factors needed for survival or differ-
entiation. 
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